Figure 1. MRI appearances of brain metastases before (pre-TCH, above) and after drug treatment (post-TCH, below). Fluid attenuated inversion recovery (FLAIR) images are shown at left, and T1-weighted images at right.
| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website http://www.wjon.org |
Case Report
Volume 4, Number 2, April 2013, pages 122-125
Complete Radiologic Response of Bulky Cerebral Metastases From Newly Diagnosed HER2-Positive Breast Cancer to Upfront Trastuzumab-Based Chemotherapy
Figure
Table
| Drug | Reported efficacy in solid tumour cerebral metastases | MWt (Da) |
|---|---|---|
| The putative blood-brain barrier cut-off is 400 Da. MWt: molecular weight; Da: daltons. | ||
| Capecitabine | + | 360 |
| Carboplatin | + | 371 |
| Tamoxifen | + | 372 |
| Megestrol acetate | + | 384 |
| Gefitinib | + | 447 |
| Doxorubicin | - | 580 |
| Etoposide | + | 587 |
| Docetaxel | - | 808 |
| Lapatinib | + | 944 |
| Trastuzumab | + | 148,000 |